Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
Immunotherapy using dendritic cells (DCs) is a promising treatment modality for cancer. However, the limited number of functional DCs from peripheral blood has been linked to the unsatisfactory clinical efficacies of current DC-based cancer immunotherapies. We previously generated proliferating anti...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1814620 |
id |
doaj-97057ff2950a43e8858f76e78e9bec65 |
---|---|
record_format |
Article |
spelling |
doaj-97057ff2950a43e8858f76e78e9bec652021-09-24T14:41:25ZengTaylor & Francis GroupOncoImmunology2162-402X2020-01-019110.1080/2162402X.2020.18146201814620Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor responseHiroaki Mashima0Rong Zhang1Tsuyoshi Kobayashi2Yuichiro Hagiya3Hirotake Tsukamoto4Tianyi Liu5Tatsuaki Iwama6Masateru Yamamoto7Chiahsuan Lin8Ryusuke Nakatsuka9Yuta Mishima10Noriko Watanabe11Takashi Yamada12Satoru Senju13Shin Kaneko14Alimjan Idiris15Tetsuya Nakatsura16Hideki Ohdan17Yasushi Uemura18National Cancer CenterNational Cancer CenterHiroshima UniversityAGC IncKumamoto UniversityChinese PLA General HospitalNational Cancer CenterNational Cancer CenterNational Cancer CenterKansai Medical UniversityKyoto UniversityBrightpath Biotherapeutics Co., LtdBrightpath Biotherapeutics Co., LtdKumamoto UniversityKyoto UniversityAGC IncNational Cancer CenterHiroshima UniversityNational Cancer CenterImmunotherapy using dendritic cells (DCs) is a promising treatment modality for cancer. However, the limited number of functional DCs from peripheral blood has been linked to the unsatisfactory clinical efficacies of current DC-based cancer immunotherapies. We previously generated proliferating antigen-presenting cells (APCs) by genetically engineering myeloid cells derived from induced pluripotent stem cells (iPSC-pMCs), which offer infinite functional APCs for broad applications in cancer therapy. Herein, we aimed to further enhance the antitumor effect of these cells by genetic modification. GM-CSF gene transfer did not affect the morphology, or surface phenotype of the original iPSC-pMCs, however, it did impart good viability to iPSC-pMCs. The resultant cells induced GM-CSF-dependent CD8+ T cell homeostatic proliferation, thereby enhancing antigen-specific T cell priming in vitro. Administration of the tumor antigen-loaded GM-CSF-producing iPSC-pMCs (GM-pMCs) efficiently stimulated antigen-specific T cells and promoted effector cell infiltration of the tumor tissues, leading to an augmented antitumor effect. To address the potential tumorigenicity of iPSC-derived products, irradiation was applied and found to restrict the proliferation of GM-pMCs, while retaining their T cell-stimulatory capacity. Furthermore, the irradiated cells exerted an antitumor effect equivalent to that of bone marrow-derived DCs obtained from immunocompetent mice. Additionally, combination with immune checkpoint inhibitors increased the infiltration of CD8+ or NK1.1+ effector cells and decreased CD11b+/Gr-1+ cells without causing adverse effects. Hence, although GM-pMCs have certain characteristics that differ from endogenous DCs, our findings suggest the applicability of these cells for broad clinical use and will provide an unlimited source of APCs with uniform quality.http://dx.doi.org/10.1080/2162402X.2020.1814620cancer immunotherapycancer vaccinedendritic cellgm-csfinduced pluripotent stem cell |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hiroaki Mashima Rong Zhang Tsuyoshi Kobayashi Yuichiro Hagiya Hirotake Tsukamoto Tianyi Liu Tatsuaki Iwama Masateru Yamamoto Chiahsuan Lin Ryusuke Nakatsuka Yuta Mishima Noriko Watanabe Takashi Yamada Satoru Senju Shin Kaneko Alimjan Idiris Tetsuya Nakatsura Hideki Ohdan Yasushi Uemura |
spellingShingle |
Hiroaki Mashima Rong Zhang Tsuyoshi Kobayashi Yuichiro Hagiya Hirotake Tsukamoto Tianyi Liu Tatsuaki Iwama Masateru Yamamoto Chiahsuan Lin Ryusuke Nakatsuka Yuta Mishima Noriko Watanabe Takashi Yamada Satoru Senju Shin Kaneko Alimjan Idiris Tetsuya Nakatsura Hideki Ohdan Yasushi Uemura Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response OncoImmunology cancer immunotherapy cancer vaccine dendritic cell gm-csf induced pluripotent stem cell |
author_facet |
Hiroaki Mashima Rong Zhang Tsuyoshi Kobayashi Yuichiro Hagiya Hirotake Tsukamoto Tianyi Liu Tatsuaki Iwama Masateru Yamamoto Chiahsuan Lin Ryusuke Nakatsuka Yuta Mishima Noriko Watanabe Takashi Yamada Satoru Senju Shin Kaneko Alimjan Idiris Tetsuya Nakatsura Hideki Ohdan Yasushi Uemura |
author_sort |
Hiroaki Mashima |
title |
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response |
title_short |
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response |
title_full |
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response |
title_fullStr |
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response |
title_full_unstemmed |
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response |
title_sort |
generation of gm-csf-producing antigen-presenting cells that induce a cytotoxic t cell-mediated antitumor response |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2020-01-01 |
description |
Immunotherapy using dendritic cells (DCs) is a promising treatment modality for cancer. However, the limited number of functional DCs from peripheral blood has been linked to the unsatisfactory clinical efficacies of current DC-based cancer immunotherapies. We previously generated proliferating antigen-presenting cells (APCs) by genetically engineering myeloid cells derived from induced pluripotent stem cells (iPSC-pMCs), which offer infinite functional APCs for broad applications in cancer therapy. Herein, we aimed to further enhance the antitumor effect of these cells by genetic modification. GM-CSF gene transfer did not affect the morphology, or surface phenotype of the original iPSC-pMCs, however, it did impart good viability to iPSC-pMCs. The resultant cells induced GM-CSF-dependent CD8+ T cell homeostatic proliferation, thereby enhancing antigen-specific T cell priming in vitro. Administration of the tumor antigen-loaded GM-CSF-producing iPSC-pMCs (GM-pMCs) efficiently stimulated antigen-specific T cells and promoted effector cell infiltration of the tumor tissues, leading to an augmented antitumor effect. To address the potential tumorigenicity of iPSC-derived products, irradiation was applied and found to restrict the proliferation of GM-pMCs, while retaining their T cell-stimulatory capacity. Furthermore, the irradiated cells exerted an antitumor effect equivalent to that of bone marrow-derived DCs obtained from immunocompetent mice. Additionally, combination with immune checkpoint inhibitors increased the infiltration of CD8+ or NK1.1+ effector cells and decreased CD11b+/Gr-1+ cells without causing adverse effects. Hence, although GM-pMCs have certain characteristics that differ from endogenous DCs, our findings suggest the applicability of these cells for broad clinical use and will provide an unlimited source of APCs with uniform quality. |
topic |
cancer immunotherapy cancer vaccine dendritic cell gm-csf induced pluripotent stem cell |
url |
http://dx.doi.org/10.1080/2162402X.2020.1814620 |
work_keys_str_mv |
AT hiroakimashima generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT rongzhang generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT tsuyoshikobayashi generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT yuichirohagiya generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT hirotaketsukamoto generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT tianyiliu generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT tatsuakiiwama generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT masateruyamamoto generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT chiahsuanlin generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT ryusukenakatsuka generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT yutamishima generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT norikowatanabe generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT takashiyamada generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT satorusenju generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT shinkaneko generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT alimjanidiris generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT tetsuyanakatsura generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT hidekiohdan generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse AT yasushiuemura generationofgmcsfproducingantigenpresentingcellsthatinduceacytotoxictcellmediatedantitumorresponse |
_version_ |
1717369772511854592 |